title: Bronchial asthma: is personalized therapy on the horizon?
abstract: In the last years there is an increasing trend towards personalized medicine for patients with asthma. This is due to the availability of novel specific therapies. These new compounds are supposed to be used in well-defined patient groups, which are likely to respond to these interventions. In addition to already used anti-IgE, novel monoclonal antibodies such as anti-IL-5 and anti-IL-13 are becoming available. Currently clinical trials are ongoing to identify which patient population will respond to these novel therapies.
authors.affiliation: Department of Pulmonology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
authors.forename: Christian
authors.initials: C
authors.lastname: Taube
keywords: Asthma; Inflammation; Monoclonal antibodies; Phenotypes